# Mannkind Corp: overview

MNKD · Nasdaq · CIK 899460 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mnkd.md) · [Financials](/companies/mnkd/financials.md) · [Filings](/companies/mnkd/filings.md) · [Insiders](/companies/mnkd/insiders.md)

Latest reported revenue: [$109.4m](/filings/0001193125-26-335054.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-335054).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [70.1](/filings/0001193125-25-265813.md) | [76.8 d](/filings/0001193125-26-073516.md) | [78.4](/filings/0001193125-26-208916.md) | [76.5](/filings/0001193125-26-335054.md) | [82.1](/filings/0001193125-25-265813.md) | [112 d](/filings/0001193125-26-073516.md) | [90.2](/filings/0001193125-26-208916.md) | [109](/filings/0001193125-26-335054.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [18.2%](/filings/0001193125-25-265813.md) | [34.5% d](/filings/0001193125-26-073516.md) | [28.5%](/filings/0001193125-26-208916.md) | [6.9%](/filings/0001193125-26-335054.md) | [23.0%](/filings/0001193125-25-265813.md) | [(6.9%) d](/filings/0001193125-26-073516.md) | [(1.8%)](/filings/0001193125-26-208916.md) | [(0.3%)](/filings/0001193125-26-335054.md) |
| Net margin | % | [16.5%](/filings/0001193125-25-265813.md) | [9.7% d](/filings/0001193125-26-073516.md) | [16.8%](/filings/0001193125-26-335054.md) | [0.9%](/filings/0001193125-26-335054.md) | [9.7%](/filings/0001193125-25-265813.md) | [(14.2%) d](/filings/0001193125-26-073516.md) | [(18.4%)](/filings/0001193125-26-335054.md) | [(17.4%)](/filings/0001193125-26-335054.md) |
| Diluted EPS | $ per share | [0.04](/filings/0001193125-25-265813.md) | not reported | [0.04](/filings/0001193125-26-208916.md) | [0.00](/filings/0001193125-26-335054.md) | [0.03](/filings/0001193125-25-265813.md) | not reported | [(0.05)](/filings/0001193125-26-208916.md) | [(0.06)](/filings/0001193125-26-335054.md) |
| Free cash flow | $m | [7.9 d](/filings/0001193125-25-265813.md) | [19.7 d](/filings/0001193125-26-073516.md) | [(6.7)](/filings/0001193125-26-208916.md) | [7.8 d](/filings/0001193125-26-335054.md) | [22.5 d](/filings/0001193125-25-265813.md) | [(10.0) d](/filings/0001193125-26-073516.md) | [(7.2)](/filings/0001193125-26-208916.md) | [(23.5) d](/filings/0001193125-26-335054.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [75.4](/filings/0000950170-24-021423.md) | [99.8](/filings/0000950170-25-027735.md) | [199](/filings/0001193125-26-073516.md) | [286](/filings/0001193125-26-073516.md) | [349](/filings/0001193125-26-073516.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(62.3%)](/filings/0000950170-24-021423.md) | [(64.3%)](/filings/0000950170-25-027735.md) | [4.4%](/filings/0001193125-26-073516.md) | [25.4%](/filings/0001193125-26-073516.md) | [11.1%](/filings/0001193125-26-073516.md) |
| Net margin | % | [(107.3%)](/filings/0000950170-24-021423.md) | [(87.6%)](/filings/0000950170-25-027735.md) | [(6.0%)](/filings/0001193125-26-073516.md) | [9.7%](/filings/0001193125-26-073516.md) | [1.7%](/filings/0001193125-26-073516.md) |
| Diluted EPS | $ per share | [(0.32)](/filings/0000950170-24-021423.md) | [(0.34)](/filings/0000950170-25-027735.md) | [(0.04)](/filings/0001193125-26-073516.md) | [0.10](/filings/0001193125-26-073516.md) | [0.02](/filings/0001193125-26-073516.md) |
| Free cash flow | $m | [(73.2)](/filings/0000950170-24-021423.md) | [(88.3)](/filings/0000950170-25-027735.md) | [(8.3)](/filings/0001193125-26-073516.md) | [32.8](/filings/0001193125-26-073516.md) | [13.7](/filings/0001193125-26-073516.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mnkd/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $136.9m | 32,133,223 |  | Added +3,532,225 |
| [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $76.7m | 18,000,000 |  | Added +14,379,587 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $68.9m | 16,174,043 |  | Reduced −2,509,440 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $56.1m | 13,169,392 |  | Added +278,326 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $33.9m | 7,947,203 |  | Added +442,056 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $33.4m | 7,844,807 |  | Added +4,561,628 |
| [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $28.1m | 6,600,000 |  | Added +700,000 |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $25.6m | 6,000,000 |  | New +6,000,000 |
| [180 WEALTH ADVISORS, LLC](/funds/1730817.md) | 2026-06-30 | $21.1m | 4,959,351 |  | Added +667,648 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $17.5m | 4,101,046 |  | Added +620,082 |

## Recent filings

[All 1,347 filings](/companies/mnkd/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-21 | 16:10 ET | [8-K](/filings/0001193125-26-361105.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-361105 |
| 2026-08-05 | 16:07 ET | [10-Q](/filings/0001193125-26-335054.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335054 |
| 2026-08-05 | 16:03 ET | [8-K](/filings/0001193125-26-335016.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335016 |
| 2026-07-24 | 16:01 ET | [8-K](/filings/0001193125-26-316041.md) | 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-316041 |
| 2026-06-02 | 08:00 ET | [8-K](/filings/0001193125-26-252544.md) | 8.01 Other events | 0001193125-26-252544 |
| 2026-05-28 | 08:37 ET | [8-K](/filings/0001193125-26-243074.md) | 8.01 Other events | 0001193125-26-243074 |
| 2026-05-22 | 17:17 ET | [8-K](/filings/0001193125-26-237183.md) | 5.07 Shareholder vote results | 0001193125-26-237183 |
| 2026-05-06 | 16:05 ET | [10-Q](/filings/0001193125-26-208916.md) | Quarterly report, period 2026-03-31 | 0001193125-26-208916 |
| 2026-05-06 | 16:03 ET | [8-K](/filings/0001193125-26-208910.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-208910 |
| 2026-04-07 | 16:30 ET | [DEF 14A](/filings/0001193125-26-145613.md) | Proxy statement, period 2026-04-07 | 0001193125-26-145613 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-073516.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/bb959301-d4d4-4f6a-92dd-f843afa76140)

## About the filer

- CIK: 899460
- Tickers: MNKD
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.